Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Pyrotinib|Breast Diseases|Vinorelbine|HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib 320mg + Vinorelbine|DRUG: Pyrotinib 400mg + Vinorelbine|DRUG: Pyrotinib plus Vinorelbine
Sponsor: Sun Yat-sen University